Explore this article's sources with AI
Follow PeptideMethods on Google
What Semaglutide actually costs in the US
Current Wegovy and Ozempic program prices range from temporary $199 starter fills to $349 or $499 monthly pen prices, with coverage-specific savings.
Why we wrote this. Semaglutide price searches mix brands, temporary offers, insurance copays, and compounded products. This page separates the current first-party figures and their eligibility limits.
In this article (10 sections)
- TL;DR
- The current manufacturer prices
- What commercial insurance can change
- Wegovy and Ozempic are not price substitutes
- Medicare and other public coverage
- Cash price and full treatment cost are different
- Why compounded semaglutide prices are separate
- How to verify your actual cost
- What we do not yet know
- Medical and regulatory disclaimers
There is no single US price for semaglutide. On 11 November 2026, Novo Nordisk's official pages listed different program prices for Wegovy and Ozempic pens. New self-pay patients could pay $199 per month for the first two monthly fills of eligible starter strengths. After that, the published Wegovy pen price was $349 per month, while Ozempic was $349 for the 0.25 mg, 0.5 mg, or 1 mg pen and $499 for the 2 mg pen.[1][2]
Those are manufacturer-program amounts, not universal pharmacy cash prices. Commercially insured patients may pay as little as $25, but savings are capped at $100 per month and eligibility restrictions apply. Government beneficiaries are excluded from the ordinary commercial offer. The real patient cost depends on the named product and prescribed presentation. Insurance benefits, the dispensing pharmacy, deductibles, and program eligibility also matter.
TL;DR
Start by separating Wegovy from Ozempic. Both contain semaglutide, but they are different FDA-approved products. Their indications and presentations differ, as do coverage decisions and manufacturer programs. A $199 introductory amount is temporary. A $25 copay claim requires eligible commercial coverage. An online compounded-vial price is not a lower quote for either approved product.
The current manufacturer prices
NovoCare's Wegovy page listed the pen at $199 per month for the first two monthly fills for new patients using 0.25 mg or 0.5 mg. The offer was stated to run through 31 December 2026. It then listed $349 per month for Wegovy pen strengths from 0.25 mg through 2.4 mg and $399 for the Wegovy HD 7.2 mg pen.[1]
The Ozempic page used the same $199 introductory amount for the first two monthly fills of the 0.25 mg and 0.5 mg pen. Its subsequent self-pay schedule was $349 per month for the 0.25 mg, 0.5 mg, or 1 mg pen and $499 per month for the 2 mg pen.[2]
A month in these pen programs is one box. The manufacturer can modify or cancel the programs, and the introductory price has a stated end date. A person starting late in December should not assume two discounted fills will remain available after the offer expires. The dispensing pharmacy should confirm the applicable amount before filling.
These prices also should not be combined into one average semaglutide figure. The product and strength determine the listed self-pay program. Averaging Ozempic 2 mg with Wegovy starter pens would erase the choice that actually controls the quoted amount.
What commercial insurance can change
Both official savings pages advertised a patient payment as low as $25 per month when commercial insurance covers the product. Both capped manufacturer savings at $100 per month. Ozempic's page described use for a prescription of up to three months, with one month defined as one pen box. Wegovy likewise defined a month as one box of four pens for the applicable injection product.[1][2]
As little as $25 is not a promise that every eligible person pays $25. If a plan's required patient share is much higher, a $100 monthly assistance cap can leave a substantial balance. Deductibles and coinsurance can change the final amount. So can a nonpreferred tier or out-of-network pharmacy.
The savings offer also does not make an insurer cover the prescription. Coverage comes first. A plan can require prior authorization, limit coverage to an FDA-approved indication, apply step therapy, or exclude a weight-management benefit. The manufacturer card can reduce an eligible covered patient's share within its terms, but it cannot rewrite the formulary.
Wegovy and Ozempic are not price substitutes
The current FDA label data identifies Wegovy as a semaglutide product for specific chronic weight-management and cardiovascular-risk indications. Ozempic has separate labeled uses in type 2 diabetes. Its label also covers cardiovascular and kidney-risk reduction in defined adults.[3][4]
A lower program price for one brand does not mean it can be prescribed or reimbursed as a substitute for the other. Product selection is a clinical decision tied to approved uses and the patient's circumstances. The insurer then applies the benefit rules for that exact product and indication.
This distinction is especially important when a quote says only semaglutide. Ask whether it refers to Wegovy, Ozempic, another approved semaglutide presentation, or a compounded product. Without the brand, dosage form, strength, and package quantity, two dollar figures may describe different objects.
Medicare and other public coverage
The standard commercial savings terms exclude government beneficiaries. Novo Nordisk's Wegovy page separately advertised a $50 monthly route for eligible Medicare patients prescribed Wegovy for a covered FDA-approved indication. The page says CMS determines eligibility and expressly states that the information is not a guarantee of coverage.[1]
That separate route should not be described as a general $50 Medicare copay. Coverage turns on the covered indication and the person's benefit, followed by the program's eligibility decision. Medicaid and VA have their own rules. The same is true for TRICARE and other public programs. A commercial coupon cannot be applied merely because public coverage leaves a high patient share.
There is no US equivalent of one NHS reimbursement rule for everyone. The closest practical comparison is a set of payer-specific criteria: a plan formulary, the covered indication, prior-authorization questions, network requirements, and the member's cost-sharing stage. Two patients with the same prescription can therefore receive different coverage decisions and pay different amounts.
Cash price and full treatment cost are different
The official self-pay amounts cover the specified medicine package through the program route. They do not automatically include a clinician visit, telehealth subscription, laboratory work, nutrition services, or other care. A bundled clinic price should itemize those services before it is compared with a pharmacy-only amount.
A conventional retail cash quote outside the manufacturer program can also differ. Pharmacies set their own usual-and-customary prices and may accept different discount arrangements. Any comparison should use the same brand and strength, plus the same package and date. A coupon search result without those fields is not a reliable benchmark.
The relevant number is the amount due for the next fill, not the highest list price or lowest advertisement found online. Ask the pharmacy to identify the submitted insurance claim, plan payment, manufacturer assistance, and patient balance separately. That makes it clear whether a low amount comes from insurance, a temporary offer, or both.
Why compounded semaglutide prices are separate
Compounded products are not FDA-approved versions of Wegovy or Ozempic. Their quotes can bundle a vial, supplies, membership, and clinical service. The amount, concentration, formulation, pharmacy, and package may differ. A monthly figure cannot be compared with an approved pen until every component is identified.
A research seller price is even less comparable. A checkout page does not establish identity or sterility. It also cannot establish lawful dispensing or equivalence to an FDA-approved product. We do not name sellers or calculate per-dose bargains from unverified vials because that would turn a pricing explainer into a buying guide for products outside the regulated route.
For the broader evidence profile, read our semaglutide guide. For federal context, use the United States regulation hub. Our semaglutide import guide explains why a foreign product is not automatically the same US-approved package.
How to verify your actual cost
First, write down the exact product and dosage form, as well as the strength and package. Next, ask the insurer whether that product is on the formulary for the prescribed indication and whether prior authorization or step therapy applies. Finally, ask the pharmacy for the amount after the plan adjudicates the claim.
If a savings program is used, ask for its expiration date, maximum monthly benefit, refill limit, and public-insurance exclusion. Confirm what the payment becomes after any introductory fills. A $199 first-fill quote is incomplete if the next expected amount is $349 or $499.
For a denial, read the reason rather than assuming the medicine is never covered. The issue may be a missing authorization, an excluded indication, a nonpreferred product, or a benefit exclusion. The notice should identify the appeal or review process. Manufacturer support can help explain its own program, but the health plan controls its coverage decision.
What we do not yet know
The public program pages do not reveal every insurer's negotiated amount, every pharmacy's cash quote, or the distribution of patient payments. They also cannot predict a specific person's deductible position or whether authorization will be approved. These are current reference points, not a national price survey.
The published offers can change after 31 December 2026, and new presentations can create new price tiers. Quarterly updates should recheck the exact pen terms, public-coverage route, commercial-assistance cap, and any stated end date rather than carrying old numbers forward.
As of 11 November 2026, the clearest first-party answer is this: eligible new self-pay patients were offered two $199 starter-strength fills, followed by published monthly pen prices of $349 for Wegovy, $349 for lower-dose Ozempic pens, or $499 for Ozempic 2 mg. Eligible commercially insured patients could pay as little as $25, subject to a $100 monthly savings cap. None of those amounts applies universally.
Medical and regulatory disclaimers
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Regulatory disclaimer: This page reflects our understanding of the regulatory status and manufacturer pricing as of 11 November 2026. Regulations and prices change. Verify with the official regulator, insurer, and dispensing pharmacy before making any decision. PeptideMethods.com is not a law firm and does not provide legal advice.
Frequently asked
How much does Wegovy cost without insurance?
On 11 November 2026, the manufacturer offered eligible new patients two $199 monthly fills at starter strengths, then listed $349 per month for standard Wegovy pens. Terms can change.
How much does Ozempic cost without insurance?
The manufacturer listed two $199 starter-strength monthly fills for eligible new patients, then $349 for 0.25 mg, 0.5 mg, or 1 mg pens and $499 for the 2 mg pen.
Can insured patients pay $25 for semaglutide?
Eligible commercially insured patients may pay as little as $25, but manufacturer savings are capped at $100 per month and do not make a plan cover the product.
Does Medicare cover Wegovy for $50 a month?
The manufacturer advertises a separate $50 route for some eligible Medicare patients using Wegovy for a covered FDA-approved indication. CMS determines eligibility, and the page says this is not a coverage guarantee.
Are compounded semaglutide prices comparable?
Not directly. Compounded products are not FDA approved, and quotes may cover different concentrations, packages, pharmacies, supplies, and clinical services.
Sources
- [1]Novo Nordisk NovoCare: current Wegovy savings and self-pay termsTier 1 · primary↩
- [2]Novo Nordisk NovoCare: current Ozempic savings and self-pay termsTier 1 · primary↩
- [3]FDA structured product label data for Wegovy (semaglutide)Tier 1 · primary↩
- [4]FDA structured product label data for Ozempic (semaglutide)Tier 1 · primary↩
No revisions yet. First published .